ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.70
+3.70%0
Insider buys (3m)
12
Insider sells (3m)
-$11.4M
Net value (3m)
-26.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 16, 2026 | BALL KRISTINE M · director | A-Award | 23,394 | $39 |
| Oct 5, 2026 | Garland J. Scott · director | Sale | 13,000 | $47 |
| Oct 5, 2026 | Garland J. Scott · director | M-Exempt | 13,000 | $15 |
| Sep 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 240 | $51 |
| Sep 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 3,535 | $50 |
| Sep 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 2,916 | $50 |
| Sep 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 289 | $51 |
| Sep 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 1,844 | $51 |
| Sep 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 | $2.48 |
| Sep 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 3,982 | $15 |
| Sep 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 2,194 | $51 |
| Aug 19, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 1,100 | $59 |
| Aug 19, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 3,900 | $58 |
| Aug 19, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 1,388 | $59 |
| Aug 19, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 4,630 | $58 |
| Aug 19, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 | $2.48 |
| Aug 6, 2026 | Derynck Mika K · director | Sale | 158,795 | $60 |
| Aug 6, 2026 | Derynck Mika K · director | M-Exempt | 20,491 | $22 |
| Aug 6, 2026 | Derynck Mika K · director | M-Exempt | 87,373 | $2.48 |
| Aug 6, 2026 | Derynck Mika K · director | M-Exempt | 27,567 | $25 |
| Aug 6, 2026 | Derynck Mika K · director | M-Exempt | 23,364 | $15 |
| Jul 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 459 | $52 |
| Jul 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 63 | $54 |
| Jul 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 324 | $50 |
| Jul 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 123 | $54 |
| Jul 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 2,638 | $53 |
| Jul 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 | $2.48 |
| Jul 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | Sale | 369 | $51 |
| Jul 21, 2026 | Collins Helen Louise · officer: CHIEF MEDICAL OFFICER | Sale | 2,063 | $52 |
| Jul 21, 2026 | Hohl Benjamin · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 1,072 | $2.48 |
Institutional positioning
13F filings over the trailing two quarters
New 129Increased 147Reduced 88Sold out 18
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 10,025,017 | Aug 13, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 7,959,538 | May 15, 2026 |
| FMR LLC | Reduced | 6,829,246 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 6,776,632 | Aug 14, 2026 |
| Polar Capital Holdings Plc | Increased | 6,430,636 | Aug 14, 2026 |
| POLAR CAPITAL HOLDINGS PLC | Increased | 5,065,933 | May 15, 2026 |
| BlackRock, Inc. | Increased | 4,359,704 | Aug 7, 2026 |
| Vestal Point Capital, LP | Increased | 4,000,000 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 3,684,707 | May 13, 2026 |
| COMMODORE CAPITAL LP | Reduced | 3,275,000 | May 15, 2026 |
| Commodore Capital LP | Unchanged | 3,275,000 | Aug 14, 2026 |
| VESTAL POINT CAPITAL, LP | Reduced | 3,250,000 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 2,903,907 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,569,002 | Aug 13, 2026 |
| BELLEVUE GROUP AG | New Position | 2,320,867 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 16, 2026